a) Article titles and abstracts were screened according to the following criteria: b) Clinical articles reporting original data, thereby excluding reviews and case reports c) Data only from adult patients EAONO position statement on Vestibular Schwannoma: Imaging Assessment Question: How should growth of Vestibular Schwannoma be defined?
d) Series using conservative management; microsurgery, radiosurgery, or fractioned stereotactic radiotherapy; and single and/or combined treatment for solitary VS e) More than 50 patients included f ) Quantitative assessment of VS growth as one of the primary study end-points g) Mean follow-up of at least 3 years h) Studies in which the reported data included patients with neurofibromatosis type 2; if these data could not be separately identified from the reported data for patients with VS, the articles were excluded.
After the initial search, 763 articles were obtained, but 721 did not meet one or more of the inclusion criteria and hence were discarded. The remaining 41 articles were reviewed for methodology and scored using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [1] .
INTRODUCTION
The relevance of defining the growth of VS is that any significant VS growth may impact the treatment strategy. A conservative treatment strategy is often proposed as a primary treatment option in the management of VS. Several authors have demonstrated that a significant proportion of VS do not grow, and those that do, usually grow slowly. Surgical and/or radiosurgical treatment options may be offered to the patient according to VS growth. Therefore, the definition of VS growth is a determinant in managing treatment strategies.
Evidence
The reviewed articles selected to find an answer how should VS growth be defined comprised 2 meta-analysis, 6 cohort studies, and 33 case series. The mean number of patients included for the clinical series was 215 (50-2500). Volumetric measurements using three-dimensional reconstruction VS: vestibular schwannoma; VDT volume doubling time; AAO-HNS American Academy of Otolaryngology-Head and Neck Surgery • *Volume measurements estimated by the slice area method. Tumor areas were measured in each slice of gadolinium-enhanced magnetic resonance imaging (MRI) scans throughout the entire tumor. Each slide volume was estimated by multiplying the slice area by the slice interval, and the tumor volume was calculated by summarizing all slices. • $Volume measurement: (A × B × C)/2 A: anteroposterior diameter; B: medial-to-lateral diameter; C: vertical diameter. Growth in the first year was a strong predictor of future growth and a VS volume >1.2 cm3 at presentation was also a predictor of future growth. • Remark 1: The best way to measure VS needs further investigation; measurements ought to be standardized and clearly defined, and the current growth criterion ≥1-2 mm needs to be redefined. We suggest that VS growth should instead be defined as a 3-mm linear increase in d1 on two consecutive MRI scans one year apart. • Remark 2: The present criterion for growth of a purely intrameatal tumor was the growth to an extrameatal extension tumor. • Remark 3: 2.5 mm/year is a clear indication for treatment of patients who wish to maintain hearing. • Remark 4: The A-P measurement was calculated parallel to the posterior surface of the petrous bone and the M-L measurement was calculated perpendicular to it. The size of the tumor was calculated as the square root of the product of these two diameters according to the 1995 guidelines of the AAO-HNS. • Remark 5: Contrast-enhanced T1-weighted volume measurements showed better interobserver agreement and reliability compared to the two-dimensional measurements for the assessment of VS growth. Small intracanalicular VS form an exception. When evaluating VS growth, the VS baseline characteristics should be considered, because standard deviation (%) strongly depends on VS size. The 1-or 2-mm difference commonly used to define the growth of VS in consecutive scans in two-dimensional measurements lies within the measurement error and should not direct clinical practice. • Remark 6: The maximum diameter of the CPA portion is the simplest method, and it is appropriate to represent the tumor volume in unselected tumors. The maximum diameter or axis diameter with the internal auditory canal portion are better when only small tumors (<0.5 cm3), i.e., tumors with the maximum CPA≤1 cm. • Remark 7: Measurements performed on the post-contrast axial T1 images included maximum axial diameter, maximum axial area, total tumor volume, and enhancement pattern.
An excellent correlation was found between the planar and volumetric methods.
growth that changed management strategies, values retained were 3 mm, 2.5, and 2 mm of VS growth per year in 4, 1, and 2 articles, respectively.
Although there is an overall low quality of the present studies, all highlight a significant VS growth >2 mm, and/or, 1.2 cm 3 , and/or 20% change in volume, and/or the square of the product of the 2 orthogonal diameters.
Following the GRADE system, 29 articles were considered to have a "low" level of evidence for being observational studies. Furthermore, 4 observational studies were down-graded to "very low" evidence for possible confounding factors. Finally, the 2 meta-analysis and 6 good quality observational studies were graded as "moderate" evidence.
CONCLUSION
VS growth should be measured on contrast-enhanced T1 weighted images.
Although there is an overall low quality of the present studies, all highlight a significant VS growth >2 mm, and/or 1.2 cm 3 , and/or 20% change in volume, and/or the square of the product of the 2 orthogonal diameters. We suggest that VS growth should instead change management strategies when there is a 3-mm increase in the diameter on two consecutive MRI scans 1 year apart.
Remarks
Most of the available evidence for VS growth comes from retrospective case series. The follow-up period in these series is quite heterogeneous. The VS growth rate should be assessed by VS growth per year in further prospective designed studies. Clinicians should seek to instigate national tumor registries in their countries and a common data set to facilitate international cooperation.
Position EAONO
• The 2-mm cut-off should be recommended to avoid the effect of MRI slice thickness and partial volume effects. Tumor shrinkage was defined as tumor-size reduction in any plane by at least 2 mm. • VS growth rate >3 mm/year should be considered a sign of evolution requiring a change in the treatment strategy. 
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